

W0. Introduction

W0.1

(W0.1) Give a general description of and introduction to your organization.

Important Stakeholder Disclaimer:

Some statements in this report are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, “Risk Factors,” of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Additionally, terms such as “ESG,” “impact” and “sustainability” can be subjective in nature, and there is no representation or guarantee that these terms, as used in the response, will reflect the beliefs or values, policies, principles, frameworks or preferred practices of any particular investor or other third-party or reflect market trends. Any ESG, climate or impact goals, commitments, incentives and initiatives outlined in this response are, unless explicitly stated otherwise in this response, purely voluntary, are not binding on our business and/or management and do not constitute a guarantee, promise or commitment regarding actual or potential positive impacts or outcomes.

About AbbVie:

AbbVie's mission is to discover and deliver innovative medicines and products that solve serious health issues and enhance people's lives today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, and virology in addition to products and services across our aesthetics portfolio. Our state-of-the-art research, development, and manufacturing centers across the world allow us to move the best ideas forward faster and deliver transformative change. Our global headquarters is in North Chicago, IL, United States. We pride ourselves on a long tradition of strong corporate governance and financial controls, led by our board of directors. They play an active and vital role in overseeing our strategic direction and our performance against all objectives on behalf of our stakeholders. For more information about AbbVie, please visit us at www.abbvie.com.

AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. AbbVie includes four main business units which are Operations, Research & Development (R&D), Commercial, and Headquarters. AbbVie operates thirty-six significant Operations and R&D sites. AbbVie also operates a significant number of small Commercial affiliate offices around the globe.

As we respond to the concerns of our stakeholders, we will strive to find innovative solutions that are both good for business and good for the environment. We aim to ensure that our energy management practices and provisions are respectful of local needs and concerns. We also commit to using our energy management knowledge and experience to address broader energy issues as necessary and appropriate. We will seek to use company-wide policy, standards, and management systems to assure responsible energy management programs are implemented. Stakeholder engagement and collaborative problem-solving play a central role in the development and implementation of these programs.

We prioritize environmental sustainability within and beyond AbbVie to support our patients, people and planet. Our environmental sustainability strategy is focused on reducing our environmental footprint, growing sustainably through inspiring innovation, and engaging our workforce to steward sustainability.

W0.2

(W0.2) State the start and end date of the year for which you are reporting data.

	Start date	End date
Reporting year	January 1 2022	December 31 2022

W0.3

(W0.3) Select the countries/areas in which you operate.

- Belgium
- Brazil
- Costa Rica
- France
- Germany
- Ireland
- Israel
- Italy
- Puerto Rico
- Singapore
- United States of America

W0.4

(W0.4) Select the currency used for all financial information disclosed throughout your response.

USD

W0.5

(W0.5) Select the option that best describes the reporting boundary for companies, entities, or groups for which water impacts on your business are being reported.

Companies, entities or groups over which operational control is exercised

W0.6

(W0.6) Within this boundary, are there any geographies, facilities, water aspects, or other exclusions from your disclosure?

Yes

W0.6a

(W0.6a) Please report the exclusions.

Exclusion	Please explain
Leased properties (not owned by AbbVie)	Our small commercial affiliate offices consist of leased (non-AbbVie owned) office space that support sales & marketing of pharmaceutical products and related business activities. Use of water is limited to drinking and sanitary activities common for office environments. We have estimated this volume of water and have found it to be a non-material quantity (less than 1% of total water withdrawal) relative to our water use at our global operations and research and development sites.

W0.7

(W0.7) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)?

Indicate whether you are able to provide a unique identifier for your organization.	Provide your unique identifier
Yes, an ISIN code	US00287Y1091
Yes, a Ticker symbol	ABBV

W1. Current state

W1.1

(W1.1) Rate the importance (current and future) of water quality and water quantity to the success of your business.

	Direct use importance rating	Indirect use importance rating	Please explain
Sufficient amounts of good quality freshwater available for use	Vital	Important	<p>Sufficient amounts of good quality freshwater is deemed vital to AbbVie's ability to manufacture quality medicines for our patients and to conduct research and development for our pipeline of new products. We anticipate that our future dependency on quality freshwater will increase for both direct (manufacturing and R&D) and indirect (washing, cleaning) operations. Manufacturing of biologics is a water-based process, and we anticipate that aspect of our business to grow across the long term.</p> <p>Water of limited quality is suitable for only a small fraction of AbbVie's indirect operations (rinsing, sanitation and hygiene (WASH)) and not usable for direct operations.</p>
Sufficient amounts of recycled, brackish and/or produced water available for use	Important	Important	<p>Sufficient amounts of recycled water is deemed important to AbbVie's ability to manufacture quality medicines for our patients and to conduct research and development for our pipeline of new products. We anticipate that our future dependency on recycled water will increase somewhat across the long term. Recycled water is suitable for only a small fraction of AbbVie's indirect operations and not usable for direct operations (manufacturing of our therapeutic products). However, we have implemented projects to use recycled water in selected applications (e.g., landscaping, cooling tower basins, WASH applications) which reduces the cost of our water and reduces our overall water consumption.</p> <p>Brackish water is not deemed important.</p>

W1.2

(W1.2) Across all your operations, what proportion of the following water aspects are regularly measured and monitored?

	% of sites/facilities/operations	Frequency of measurement	Method of measurement	Please explain
Water withdrawals – total volumes	100%	Quarterly	Water volumes are primarily monitored in-situ (in-line) with calibrated water meters and in some cases via interpolation.	Water withdrawals may be measured continuously or on a monthly basis at some of the operations facilities, in accordance with the local requirements. At least quarterly, each operations facility reports this data to our Global EHS organization for monitoring and alignment with company targets.
Water withdrawals – volumes by source	100%	Quarterly	Water volumes are primarily monitored in-situ (in-line) with calibrated water meters and in some cases via interpolation at the source level.	Water withdrawals may be measured continuously or on a monthly basis at some of the operations facilities, in accordance with the local requirements. At least quarterly, each operations facility reports this data to our Global EHS organization for monitoring and alignment with company targets.
Entrained water associated with your metals & mining and/or coal sector activities - total volumes [only metals and mining and coal sectors]	<Not Applicable>	<Not Applicable>	<Not Applicable>	<Not Applicable>
Produced water associated with your oil & gas sector activities - total volumes [only oil and gas sector]	<Not Applicable>	<Not Applicable>	<Not Applicable>	<Not Applicable>
Water withdrawals quality	100%	Other, please specify (Water withdrawals quality is monitored according to local water withdrawal permit requirements.)	Water withdrawals quality is primarily monitored via sampling and analysis by an accredited lab according to local water withdrawal permit requirements.	Water withdrawals quality is monitored according to local water withdrawal permit requirements. Additionally, water quality reports from the local municipalities are monitored by the site level EHS organization. For sites that are required to monitor and report this information, coverage is 100%.
Water discharges – total volumes	100%	Quarterly	Water discharge volumes are primarily monitored in-situ (in-line) with calibrated water meters and in some cases via interpolation.	Water discharges volume may be measured continuously or on a monthly basis at some of the operations facilities, in accordance with the local water discharge permit requirements. At least quarterly, each operations facility reports this data to our Global EHS organization for monitoring and alignment with company targets.
Water discharges – volumes by destination	100%	Quarterly	Water discharge volumes by destination are primarily monitored in-situ (in-line) with calibrated water meters and in some cases via interpolation.	Water discharges volume may be measured continuously or on a monthly basis at some of the operations facilities, in accordance with the local water discharge permit requirements. At least quarterly, each operations facility reports this data to our Global EHS organization for monitoring and alignment with company targets. The destination of all water discharged is monitored by the site level EHS organization.
Water discharges – volumes by treatment method	100%	Quarterly	Water discharge volumes by treatment method are primarily monitored in-situ (in-line) with calibrated water meters and in some cases via interpolation.	Water discharges volume may be measured continuously or on a monthly basis at some of the operations facilities, in accordance with the local water discharge permit requirements. At least quarterly, each operations facility reports this data to our Global EHS organization for monitoring and alignment with company targets. The volumes of all water discharged is monitored by the site level EHS organization and reported as Non-impaired or Impaired based the local treatment method.
Water discharge quality – by standard effluent parameters	100%	Other, please specify (Water discharge quality is monitored according to local water discharge permit requirements.)	Water discharge quality is primarily monitored via sampling and analysis by an accredited lab. This is based on local water standards and regulatory compliance obligations for the sites which we operate.	The monitoring of water discharge quality varies from site to site depending on whether there is an on-site wastewater treatment facility or if the discharge water is sent to a municipal water treatment facility. For sites that are required to monitor and report this information, coverage is 100%.
Water discharge quality – emissions to water (nitrates, phosphates, pesticides, and/or other priority substances)	100%	Other, please specify (Water discharge quality is monitored according to local water discharge permit requirements.)	Water discharge quality is primarily monitored via sampling and analysis by an accredited lab. This is based on local water standards and regulatory compliance obligations for the sites which we operate.	The monitoring of water discharge quality varies from site to site depending on whether there is an on-site wastewater treatment facility or if the discharge water is sent to a municipal water treatment facility. For sites that are required to monitor and report this information, coverage is 100%.
Water discharge quality – temperature	100%	Other, please specify (Water discharge quality is monitored according to local water discharge permit requirements.)	Water quality is primarily monitored for temperature verification by in-line digital thermometers. This is based on local water standards and regulatory compliance obligations for the sites which we operate.	For sites that are required to monitor and report this information, coverage is 100%.
Water consumption – total volume	100%	Quarterly	Water consumption volumes are primarily calculated by subtractive methods at our sites.	At least quarterly, each operations facility reports this data to our Global EHS organization for monitoring and alignment with company targets. Where the consumption amount is negligible for a site, we assume the amount from that facility to be zero.
Water recycled/reused	1-25	Quarterly	Water volumes are primarily monitored in-situ (in-line) with calibrated water meters and in some cases via interpolation.	At least quarterly, each operations facility reports this data to our Global EHS organization for monitoring and alignment with company targets. Recycled/reused water volumes would be reflected in the total water consumption (reduction data). Only selected sites have water recycling capabilities.
The provision of fully-functioning, safely managed WASH services to all workers	100%	Other, please specify (Water quality is monitored according to local water permit requirements.)	Water quality is primarily monitored for verification purposes via sampling and analysis for key influent parameters (e.g., chlorine, solids) with water test calibration kits.	Safely managed WASH services are available to employees at all global locations.

(W1.2b) What are the total volumes of water withdrawn, discharged, and consumed across all your operations, how do they compare to the previous reporting year, and how are they forecasted to change?

	Volume (megaliters/year)	Comparison with previous reporting year	Primary reason for comparison with previous reporting year	Five-year forecast	Primary reason for forecast	Please explain
Total withdrawals	28942	Much lower	Increase/decrease in business activity	About the same	Increase/decrease in business activity	There was a 25% decrease from 38,371.90 megaliters/year in 2021 to 28,942 megaliters/year in 2022. This decrease in 2022 was mainly driven by the decrease in non-contact cooling water use, which is returned to the source in the same amount and with the same quality as withdrawn. In 2022, AbbVie discontinued the manufacture of a legacy product at our North Chicago manufacturing site, which had required our most energy and water intensive manufacturing process.
Total discharges	27675.3	Much lower	Increase/decrease in business activity	About the same	Increase/decrease in business activity	There was a 26% decrease from 37,391.6 megaliters/year in 2021 to 27,675.3 megaliters/year in 2022. This decrease in 2022 was mainly driven by the decrease in non-contact cooling water use, which is returned to the source in the same amount and with the same quality as withdrawn. In 2022, AbbVie discontinued the manufacture of a legacy product at our North Chicago manufacturing site, which had required our most energy and water intensive manufacturing process.
Total consumption	1266.7	Much higher	Mergers and acquisitions	About the same	Increase/decrease in business activity	There was a 29% increase from 980.2 megaliters/year in 2021 to 1,266.7 megaliters/year in 2022. This increase was primarily driven by the addition of legacy Allergan sites in 2022. AbbVie acquired Allergan PLC in May of 2020 but the water data was added for the first time in 2022. Across our sites, we have sites with increased consumption and some with decreased consumption with an overall increase due to the addition of legacy Allergan sites.

W1.2d

(W1.2d) Indicate whether water is withdrawn from areas with water stress, provide the proportion, how it compares with the previous reporting year, and how it is forecasted to change.

	Withdrawals are from areas with water stress	% withdrawn from areas with water stress	Comparison with previous reporting year	Primary reason for comparison with previous reporting year	Five-year forecast	Primary reason for forecast	Identification tool	Please explain
Row 1	Yes	1-10	About the same	Mergers and acquisitions	About the same	Increase/decrease in business activity	WRI Aqueduct	There was an increase from 1.3% in 2021 to 3% in 2022. This increase was mainly driven by the addition of legacy Allergan sites in 2022. AbbVie acquired Allergan PLC in May of 2020 but the water data was added for the first time in 2022.

W1.2h

(W1.2h) Provide total water withdrawal data by source.

	Relevance	Volume (megaliters/year)	Comparison with previous reporting year	Primary reason for comparison with previous reporting year	Please explain
Fresh surface water, including rainwater, water from wetlands, rivers, and lakes	Relevant	23910	Much lower	Increase/decrease in business activity	There was a 30% decrease from 34,315.7 megaliters/year in 2021 to 23,910 in 2022. This decrease in 2022 was mainly driven by the decrease in non-contact cooling water use, which is returned to the source in the same amount and with the same quality as withdrawn. In 2022, AbbVie discontinued the manufacture of a legacy product at our North Chicago manufacturing site, which had required our most energy and water intensive manufacturing process.
Brackish surface water/Seawater	Not relevant	<Not Applicable>	<Not Applicable>	<Not Applicable>	Brackish surface water/Seawater is not an applicable withdrawal source for any AbbVie sites.
Groundwater – renewable	Relevant	1581	Much higher	Mergers and acquisitions	There was a 10% increase from 1435.8 megaliters/year in 2021 to 1581.0 megaliters/year in 2022. This increase was mainly driven by the addition of legacy Allergan sites in 2022. AbbVie acquired Allergan PLC in May of 2020 but the water data was added for the first time in 2022.
Groundwater – non-renewable	Not relevant	<Not Applicable>	<Not Applicable>	<Not Applicable>	Groundwater – non-renewable is not an applicable withdrawal source for any AbbVie sites.
Produced/Entrained water	Relevant but volume unknown	<Not Applicable>	<Not Applicable>	<Not Applicable>	Produced/Entrained water is not tracked for any AbbVie sites.
Third party sources	Relevant	3451	Much higher	Mergers and acquisitions	There was a 32% increase from 2620.4 megaliters/year in 2021 to 3451.0 megaliters/year in 2022. This increase was mainly driven by the addition of legacy Allergan sites in 2022. AbbVie acquired Allergan PLC in May of 2020 but the water data was added for the first time in 2022.

W1.2i

(W1.2i) Provide total water discharge data by destination.

	Relevance	Volume (megaliters/year)	Comparison with previous reporting year	Primary reason for comparison with previous reporting year	Please explain
Fresh surface water	Relevant	24303.3	Much lower	Increase/decrease in business activity	There was a 30% decrease from 34,714.2 megaliters/year in 2021 to 24,303.3 megaliters/year in 2022. This decrease in 2022 was mainly driven by the decrease in non-contact cooling water use, which is returned to the source in the same amount and with the same quality as withdrawn. In 2022, AbbVie discontinued the manufacture of a legacy product at our North Chicago manufacturing site, which had required our most energy and water intensive manufacturing process.
Brackish surface water/seawater	Not relevant	<Not Applicable>	<Not Applicable>	<Not Applicable>	Brackish surface water/Seawater is not an applicable discharge destination for any AbbVie sites.
Groundwater	Relevant	173.6	Much lower	Increase/decrease in business activity	There was a 12% decrease from 197.2 megaliters/year in 2021 to 173.6 megaliters/year in 2022. Water discharged to groundwater only accounts for less than 1% of our total water discharged. Across our sites, we have sites with increased groundwater discharges and some with decreased discharges with an overall decrease with the addition of legacy Allergan sites.
Third-party destinations	Relevant	3198.4	Much higher	Mergers and acquisitions	There was a 29% increase from 2,480.2 megaliters/year in 2021 to 3,198.4 megaliters/year in 2022. This increase was mainly driven by the addition of legacy Allergan sites in 2022. AbbVie acquired Allergan PLC in May of 2020 but the water data was added for the first time in 2022.

W1.2j

(W1.2j) Within your direct operations, indicate the highest level(s) to which you treat your discharge.

	Relevance of treatment level to discharge	Volume (megaliters/year)	Comparison of treated volume with previous reporting year	Primary reason for comparison with previous reporting year	% of your sites/facilities/operations this volume applies to	Please explain
Tertiary treatment	Relevant	403.5	About the same	Increase/decrease in business activity	1-10	AbbVie's Campoverde, Italy site is the only site where we have full tertiary treatment capability. The site discharges treated water to a local fresh surface waterway. We monitor selected parameters such as pH, temperature, and BOD/TOC in accordance with local permit requirements before discharging to the local fresh surface waterway. There was a 1% decrease, from 405.6 megaliters/year in 2021 to 403.5 megaliters/year in 2022. Our definition for change: About the same: +/- 5%, Lower: >-5%, Much Lower: >- 10%, Higher: >+5%, Much Higher: >+10%
Secondary treatment	Relevant	1382.2	Lower	Increase/decrease in business activity	1-10	AbbVie's North Chicago and Barceloneta, Puerto Rico sites have on-site secondary wastewater treatment capability. Both sites discharge treated water to local municipal waste treatment facilities for additional treatment. We monitor selected parameters such as pH, temperature, and BOD/TOC in accordance with local permit requirements before discharging to the municipal waste treatment facilities. There was a 10% decrease, from 1,532.7 megaliters/year to 1,382.2 megaliters/year in 2022. Our definition for change: About the same: +/- 5%, Lower: >-5%, Much Lower: >- 10%, Higher: >+5%, Much Higher: >+10%
Primary treatment only	Not relevant	<Not Applicable>	<Not Applicable>	<Not Applicable>	<Not Applicable>	There are no AbbVie sites with just primary treatment capability.
Discharge to the natural environment without treatment	Relevant	23899.8	Much lower	Increase/decrease in business activity	21-30	No AbbVie site discharges wastewater to the natural environment without an adequate level of treatment. However, AbbVie does utilize non-contact cooling water at our North Chicago, Illinois and Wyandotte, Michigan sites. The non-contact cooling water does not undergo any treatment prior to being returned to the freshwater surface source. There was a 30% decrease, from 34,308.6 megaliters/year in 2021 to 23,899.8 in 2022. This decrease in 2022 was mainly driven by the decrease in non-contact cooling water use, which is returned to the source in the same amount and with the same quality as withdrawn. In 2022, AbbVie discontinued the manufacture of a legacy product at our North Chicago manufacturing site, which had required our most energy and water intensive manufacturing process. Our definition for change: About the same: +/- 5%, Lower: >-5%, Much Lower: >- 10%, Higher: >+5%, Much Higher: >+10%
Discharge to a third party without treatment	Relevant	1989.8	Much higher	Mergers and acquisitions	71-80	A majority of AbbVie sites do not have on-site waste treatment capability, and these sites discharge their wastewater to a local waste treatment facility. AbbVie sites monitor selected parameters such as pH, temperature, and BOD/TOC in accordance with local permit requirements before discharging to the third party. There was a 74% increase, from 1,144.7 megaliters/year in 2021 to 1,989.8 in 2022. This increase was mainly driven by the addition of legacy Allergan sites in 2022. AbbVie acquired Allergan PLC in May of 2020 but the water data was added for the first time in 2022. Our definition for change: About the same: +/- 5%, Lower: >-5%, Much Lower: >- 10%, Higher: >+5%, Much Higher: >+10%
Other	Not relevant	<Not Applicable>	<Not Applicable>	<Not Applicable>	<Not Applicable>	Not applicable.

W1.2k

(W1.2k) Provide details of your organization's emissions of nitrates, phosphates, pesticides, and other priority substances to water in the reporting year.

	Emissions to water in the reporting year (metric tonnes)	Category(ies) of substances included	List the specific substances included	Please explain
Row 1	5.82	Nitrates Phosphates Pesticides Priority substances listed under the EU Water Framework Directive	Benzene, Cadmium and its compounds, 1,2-dichloroethane, Dichloromethane, Hexachlorobenzene, Hexachlorobutadiene, Lead and its compounds, Mercury and its compounds, Naphthalene, Nickel and its compounds, Pentachlorophenol, Trichloromethane (chloroform)	The monitoring of water discharge quality varies from site to site depending on whether there is an on-site wastewater treatment facility or if the discharge water is sent to a municipal water treatment facility. All of our sites monitor and report this information according to the local water discharge permit requirements. Sites that are not required to monitor and report the listed substances have zero contribution to our calculations. Total nitrates: 2.91 Metric Tonnes Total phosphates: 2.85 Metric Tonnes Total pesticides: 0.002 Metric Tonnes Total priority substances: 0.056 Metric Tonnes

W1.3

(W1.3) Provide a figure for your organization's total water withdrawal efficiency.

	Revenue	Total water withdrawal volume (megaliters)	Total water withdrawal efficiency	Anticipated forward trend
Row 1	5805400000	28942	2005873.81659871	This is anticipated to stay about the same, although AbbVie has targets in place to address water efficiency and decrease our dependence on water which will also drive increase our total water withdrawal efficiency in the longer term.

W1.4

(W1.4) Do any of your products contain substances classified as hazardous by a regulatory authority?

	Products contain hazardous substances	Comment
Row 1	Yes	<Not Applicable>

W1.4a

(W1.4a) What percentage of your company's revenue is associated with products containing substances classified as hazardous by a regulatory authority?

Regulatory classification of hazardous substances	% of revenue associated with products containing substances in this list	Please explain
Candidate List of Substances of Very High Concern (UK Regulation)	Less than 10%	AbbVie products may contain substances classified as hazardous by a regulatory authority, but our drug products are subject to rigorous regulation by numerous international, federal and state authorities and the US healthcare industry, in particular, is highly regulated to ensure with overwhelming evidence that our products are safe and are of high efficacy and high quality. The percentage of our products (in terms of revenues) that contain substances on the Candidate List of Substances of Very High Concern for Authorisation above 0.1% by weight is 0.25%.

W1.5

(W1.5) Do you engage with your value chain on water-related issues?

	Engagement	Primary reason for no engagement	Please explain
Suppliers	Yes	<Not Applicable>	<Not Applicable>
Other value chain partners (e.g., customers)	No	Other, please specify (Our current focus is to engage our value chain partners to set science-based targets by 2027.)	In 2021, AbbVie made the commitment to set near-term Science Based Targets. Working with the Science Based Targets initiative (SBTi) enables access to expert resources that support the meaningful reduction of our climate impact and that provide an external assessment. In August 2022, AbbVie submitted our targets to SBTi. Our new targets, which were validated by SBTi in March 2023, include ensuring 79.1% of our suppliers (by emissions covering Purchased Goods & Services, Capital Goods, and Upstream Transportation & Distribution) will have science-based targets by 2027. Although this is not a water-related requirement, the engagement target helps ensure that our value chain partners are putting in efforts to reduce the environmental impact (including water-related impact) from their operations. We have developed a Supplier Engagement Strategy and Program to support this target. This engagement includes sending an annual supplier survey to selected top suppliers where we are collecting water consumption data from those suppliers. This survey also includes collecting target information to determine if our suppliers have set their own water related targets.

W1.5a

(W1.5a) Do you assess your suppliers according to their impact on water security?

Row 1

Assessment of supplier impact

Yes, we assess the impact of our suppliers

Considered in assessment

Basin status (e.g., water stress or access to WASH services)

Number of suppliers identified as having a substantive impact

0

% of total suppliers identified as having a substantive impact

Unknown

Please explain

In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. Water stress was included in this assessment and 35 or our most critical supplier locations were evaluated, besides the top 20 locations for our downstream third-party logistic warehouses and all 9 of our global third-party data centers. Water Stress was identified as a growing risk across those sites. Both climate change and population density will have a negative impact on the water supplies in the areas where our suppliers operate causing water supplies to become more scarce and limited. There will be a corresponding increase in the cost of water, as well as potential limitations on the amount of water that can be withdrawn. AbbVie will repeat this type of risk assessment every five years or if a significant change occurs to these locations or to the external suppliers.

W1.5b

(W1.5b) Do your suppliers have to meet water-related requirements as part of your organization's purchasing process?

	Suppliers have to meet specific water-related requirements	Comment
Row 1	No, and we do not plan to introduce water-related requirements within the next two years	In 2021, AbbVie made the commitment to set near-term Science Based Targets. Working with the Science Based Targets initiative (SBTi) enables access to expert resources that support the meaningful reduction of our climate impact and that provide an external assessment. In August 2022, AbbVie submitted our targets to SBTi. Our new targets, which were validated by SBTi in March 2023, include ensuring 79.1% of our suppliers (by emissions covering Purchased Goods & Services, Capital Goods, and Upstream Transportation & Distribution) will have science-based targets by 2027. While there is no specific water-related requirements in our supplier contracts, this suppliers engagement target helps ensure that our suppliers are putting in efforts to reduce the environmental impact (including water-related impact) from their operations.

W1.5d

(W1.5d) Provide details of any other water-related supplier engagement activity.

Type of engagement

Innovation & collaboration

Details of engagement

Encourage/incentivize innovation to reduce water impacts in products and services

% of suppliers by number

Less than 1%

% of suppliers with a substantive impact

1-25

Rationale for your engagement

AbbVie's global supplier base is expansive, totaling more than 51,000 suppliers. One supplier in a water-stressed and yet critical market in India was targeted for water-related engagement. AbbVie worked with this supplier to track wastewater effluent from AbbVie's products being made at the supplier's site. Wastewater is re-directed to an on-site reverse osmosis system, the output of which is then used for on-site landscape watering and supplemental boiler feed water.

Impact of the engagement and measures of success

For calendar year 2022, the collaboration with the supplier resulted in recycling approximately 8.109 megaliters of water. This achievement helps to make a remarkable, positive environmental impact in a water-stressed area of India.

Comment

No additional comment.

W2. Business impacts

W2.1

(W2.1) Has your organization experienced any detrimental water-related impacts?

No

W2.2

(W2.2) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations?

	Water-related regulatory violations	Fines, enforcement orders, and/or other penalties	Comment
Row 1	Yes	Fines, but none that are considered as significant	All operations facilities are required to report any water-related regulatory violations or EHS events to our Global EHS. Alerts may be distributed to the other sites if an EHS event has the potential to occur at another AbbVie location, and has been considered serious or significant. There was an event at one of our operations facility in 2022 that involved a small fine for failing to sample for several wastewater parameters during the specified window in Quarter 4 (i.e., the sample was taken outside of the timeframe). This event was caused by a confusion during a reschedule request with the service provider. A Notice of Violation (NOV) was issued and the facility was required to sample for the permit parameters for the following six consecutive months. The facility demonstrated compliance with all the parameters and has fulfilled all the NOV requirements, as well as paid for the small fine incurred. The facility has also implemented an action plan to avoid a recurrence.

W2.2a

(W2.2a) Provide the total number and financial value of all water-related fines.

Row 1

Total number of fines

1

Total value of fines

9000

% of total facilities/operations associated

3

Number of fines compared to previous reporting year

About the same

Comment

We did not report any water-related fines in CDP last year.

Our definition for comparison to previous reporting year:

About the same: +/- 5%, Lower: >-5%, Much Lower: >- 10%, Higher: >+5%, Much Higher: >+10%

W3. Procedures

W3.1

(W3.1) Does your organization identify and classify potential water pollutants associated with its activities that could have a detrimental impact on water ecosystems or human health?

	Identification and classification of potential water pollutants	How potential water pollutants are identified and classified	Please explain
Row 1	Yes, we identify and classify our potential water pollutants	<p>AbbVie is committed to monitoring our operations to ensure that the manufacture, use and disposal of our products do not adversely affect human health or the environment. AbbVie established a water management policy that requires all applicable operations facilities to conduct a Pharmaceuticals in the Environment (PiE) hazard screening to identify Active Pharmaceutical Ingredients (APIs) of potential environmental concern at the site. Our operations facilities are also required to estimate the potential concentration for the selected APIs - Process Contribution (PC) that could be released into the site wastewater stream and evaluate whether the PC is acceptable or if further mitigation actions should be implemented. Where applicable, periodical sampling for the selected APIs is also required to be completed. AbbVie also prohibits our operations facilities to discharge materials to an offsite treatment works or surface water at concentrations that could reasonably be expected to have an adverse effect on human health or the environment.</p> <p>AbbVie has developed an SOP to provide guidance for the hazard identification, risk assessment, and control of PiE for manufacturing sites per AbbVie's Position on Environmental Stewardship. Our SOP was recently updated to align with the "Responsible Manufacturing Effluent Management Technical Guidance Document", EFPIA/AESGP/Medicines for Europe as part of the Inter Associations Initiative (IAI) PiE Task Force, final draft, 01-Sep-2020.</p>	<Not Applicable>

W3.1a

(W3.1a) Describe how your organization minimizes the adverse impacts of potential water pollutants on water ecosystems or human health associated with your activities.

Water pollutant category

Other synthetic organic compounds

Description of water pollutant and potential impacts

Active Pharmaceutical Ingredients (APIs) in wastewater accumulating in rivers, lakes or any waterbodies above certain levels could impact aquatic ecosystems. AbbVie is committed to monitoring our operations to ensure that the manufacture, use and disposal of our products do not adversely affect human health or the environment.

Value chain stage

Direct operations

Actions and procedures to minimize adverse impacts

Provision of best practice instructions on product use

Please explain

The most common pathway pharmaceuticals reach the environment is through drug use by consumers or the improper disposal of expired or unused medication. We provide regulatory authorities with environmental risk assessments that are used to evaluate potential environmental risks associated with patient use of our medications.

API-contaminated wastewater could also be discharged by pharmaceutical manufacturing facilities. AbbVie requires all applicable operations facilities to conduct a Pharmaceuticals in the Environment (PiE) hazard screening to identify Active Pharmaceutical Ingredients (APIs) of potential environmental concern at the site. Our operations facilities are also required to estimate the potential concentration for the selected APIs - Process Contribution (PC) that could be released into the site wastewater stream and evaluate whether the PC is acceptable or if further mitigation actions should be implemented. Where applicable, periodical sampling for the selected APIs is also required to be completed. AbbVie also prohibits our operations facilities to discharge materials to an offsite treatment works or surface water at concentrations that could reasonably be expected to have an adverse effect on human health or the environment.

W3.3

(W3.3) Does your organization undertake a water-related risk assessment?

Yes, water-related risks are assessed

W3.3a

(W3.3a) Select the options that best describe your procedures for identifying and assessing water-related risks.

Value chain stage

Direct operations

Coverage

Full

Risk assessment procedure

Water risks are assessed as part of an established enterprise risk management framework

Frequency of assessment

Annually

How far into the future are risks considered?

More than 6 years

Type of tools and methods used

Tools on the market

Tools and methods used

WRI Aqueduct

Other, please specify (Climate Physical Risk Assessment including Water Stress)

Contextual issues considered

Water availability at a basin/catchment level

Water quality at a basin/catchment level

Implications of water on your key commodities/raw materials

Water regulatory frameworks

Status of ecosystems and habitats

Access to fully-functioning, safely managed WASH services for all employees

Other, please specify (All new products or legacy products with new formulations or indications undergo an environmental risk assessment, of which water is an integral component. This is accomplished through a mandatory, internal Technology Transfer operating standard.)

Stakeholders considered

Customers

Employees

Investors

Local communities

NGOs

Regulators

Suppliers

Water utilities at a local level

Other water users at the basin/catchment level

Other, please specify (Other parties are considered as possible interested stakeholders as they are identified. AbbVie considers all possible stakeholders to be potential current and future interested parties in water management.)

Comment

AbbVie updates a water risk assessment using the WRI Aqueduct tool on an annual basis for 100% of our operations and research and development sites. In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. Water stress was included in this assessment and 100% of our operations and research and development sites were evaluated. Water Stress was identified as a growing risk across our operational sites. Both climate change and population density will have a negative impact on the water supplies in the areas where we operate causing water supplies to become more scarce and limited. There will be a corresponding increase in the cost of water, as well as potential limitations on the amount of water that can be withdrawn. We currently have a limited number of sites in high water stress areas, but we expect that to increase to over 20 operational sites by 2050. AbbVie plans to repeat this type of risk assessment every five years or if a significant change occurs to operations locations.

Value chain stage

Supply chain

Other stages of the value chain

Coverage

Partial

Risk assessment procedure

Water risks are assessed as part of an established enterprise risk management framework

Frequency of assessment

Every three years or more

How far into the future are risks considered?

More than 6 years

Type of tools and methods used

Other

Tools and methods used

Internal company methods

External consultants

Contextual issues considered

Water availability at a basin/catchment level

Water quality at a basin/catchment level

Implications of water on your key commodities/raw materials

Water regulatory frameworks

Status of ecosystems and habitats

Access to fully-functioning, safely managed WASH services for all employees

Other, please specify (All new products or legacy products with new formulations or indications undergo an environmental risk assessment, of which water is an integral component. This is accomplished through a mandatory, internal Technology Transfer operating standard.)

Stakeholders considered

Customers

Employees

Investors

Local communities

NGOs

Regulators

Suppliers

Water utilities at a local level

Other water users at the basin/catchment level

Other, please specify (Other parties are considered as possible interested stakeholders as they are identified. AbbVie considers all possible stakeholders to be potential current and future interested parties in water management.)

Comment

In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. Water stress was included in this assessment and 35 of our most critical supplier locations were evaluated, besides the top 20 locations for our downstream third-party logistic warehouses and all 9 of our global third-party data centers. Water Stress was identified as a growing risk across those sites. Both climate change and population density will have a negative impact on the water supplies in the areas where our suppliers operate causing water supplies to become more scarce and limited. There will be a corresponding increase in the cost of water, as well as potential limitations on the amount of water that can be withdrawn. AbbVie will repeat this type of risk assessment every five years or if a significant change occurs to these locations or to the external suppliers.

We have also run a water risk assessment using the WRI Aqueduct tool for approximately 125 critical suppliers manufacturing key intermediate and active pharmaceutical ingredients, drug substances, drug products, combination products, devices and packaging processes. We are in the process of evaluating the results from this water risk assessment screening tool.

W3.3b

(W3.3b) Describe your organization’s process for identifying, assessing, and responding to water-related risks within your direct operations and other stages of your value chain.

	Rationale for approach to risk assessment	Explanation of contextual issues considered	Explanation of stakeholders considered	Decision-making process for risk response
Row 1	<p>AbbVie recognizes the importance of access to clean, safe water and sanitation, and understands the potential impacts our operations can have on this vital resource. Our patients, customers and employees depend on this increasingly scarce resource and we are committed to managing and reducing the water we use.</p> <p>AbbVie’s Global EHS organization leads specific Water Risk assessment activities on periodic basis. AbbVie uses the WRI Aqueduct Water Risk tool to assess current and future water risks in the areas that we operate on an annual basis. We also assess water-related risks of key suppliers globally. This tool was selected due to its widespread availability, its company-wide coverage of AbbVie’s direct and indirect operations, and general ease of use. The WRI Aqueduct tool was used to assess 100% of our direct and indirect water-related risks through year 2030 and 2040 (more than 10 years).</p> <p>Water stress was included in the S&P Global Trucost Climate Risk Assessment and 35 of our most critical supplier locations were evaluated, besides the top 20 locations for our downstream third-party logistic warehouses and all 9 of our global third-party data centers. These are the suppliers who provide the supply chain components for some of our top-selling products.</p>	<p>AbbVie has a well-established Risk Management program as well as a Crisis Preparedness and Business Continuity planning program. These two programs cover all of AbbVie’s operations globally. The three key steps in both programs are to</p> <ol style="list-style-type: none"> (1) analyze the business for sources of risk (2) assess the risks (3) develop strategies to address the risks. <p>Elements of prevention, preparedness, response, recovery, and sustainability are incorporated into the programs. Water-related risks are included within the risks that are addressed by these programs. AbbVie uses a Global Risk Profile approach to evaluate and prioritize a variety of risks geographically. We take an “All Hazards” approach in our evaluations, identifying risks in the following categories:</p> <ol style="list-style-type: none"> (1) Natural Hazards (including water-related risks) (2) Security / Political / Social (3) Financial and Investment <p>We also consider attendant risks to regulatory compliance, employee health & safety, and reputation with input from Public Affairs, Government Affairs, Regulatory Affairs, Legal, and EHS. The Risk Management function leads the annual process of identifying risks. Short-term, Medium-term, and Long-term are considered within this process. The Risk Management function reviews the progress of risk mitigation plans with the Executive Leadership Team on a quarterly basis.</p> <p>Water availability and quality are key to our direct operations (manufacturing of our therapeutic products) to ensure safety and quality of our products.</p>	<p>Our patients, customers, employees and the community depend on water, an increasingly scarce resource, and we are committed to managing and reducing the water we use.</p> <p>We also ensure that all of our operations facilities operate within the local water permit requirements and are in compliance with the applicable regulatory obligations.</p> <p>For AbbVie to be successful in the long term, we also work with suppliers that operate with the future in mind. For suppliers manufacturing key intermediate and active pharmaceutical ingredients, drug substances, drug products, combination products, devices and packaging processes, we require completion of an EHS checklist that covers: occupational hygiene, environmental risks, process safety, fire protection and emergency response, as well as transport. Our Global EHS organization ensures that any risks identified have action plans for mitigation, and these plans are tracked to completion to ensure that all standards are met.</p>	<p>We anticipate that climate change may have varying levels of impact on our business across the short-, medium-, and long-term. AbbVie seeks to understand and anticipate these impacts to ensure we sustain the discovery and development of innovative medicines for both current and future patients. This effort involves evaluating our operations and supply chains for potential disruptions in connection with climate change and implementing contingency plans or advance preparedness. We invest in business continuity efforts that contribute to mitigating the potential for risk of loss and promote business continuity in the event a climate-related risk materializes. AbbVie’s Crisis Preparedness and Business Continuity group develops and maintains the needed infrastructure, procedures, and practices that enable us to mitigate risks and respond to crisis events that may adversely impact our business, employees or surrounding communities. Each operating and commercial division have documented business continuity plans that address key products and operations. The overall Crisis Preparedness and Business Continuity plan is reviewed at the executive level on an annual basis, and all business continuity plans are reviewed on a biennial basis. AbbVie also invests in the assurance of supply activities including selecting redundant suppliers for raw materials, manufacturing products at multiple locations globally, and redundant shipping supply chains to deliver our products.</p>

W4. Risks and opportunities

W4.1

(W4.1) Have you identified any inherent water-related risks with the potential to have a substantive financial or strategic impact on your business?

No

W4.1a

(W4.1a) How does your organization define substantive financial or strategic impact on your business?

Substantive risks for the company are set at a much higher financial and strategic impact threshold. Substantive strategic impacts would include things that could negatively impact our product pipeline, manufacturing capabilities, regulatory compliance, employee health & safety, and our reputation. Climate risks, and their associated water-related risks, would generally be considered to have a substantive financial impact when greater than \$100 million on an annual basis, though such an impact should not be equated to or taken as a representation about "materiality" under the US federal securities laws or any similar legal or regulatory regime globally. Climate risks and water-related risks with strategic impact to the business would also be considered substantive.

Clean water is crucial for both human and environmental health, and we are committed to using water responsibly and doing our part to protect this vital resource. AbbVie acknowledges that water stress and water scarcity have a growing impact in regions around the globe include areas where we operate. In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. Water stress was included in this assessment and 100% of our operations and research and development sites were evaluated. Both climate change and population density will have a negative impact on the water supplies in the areas where we operate causing water supplies to become more scarce and limited. There will be a corresponding increase in the cost of water, as well as potential limitations on the amount of water that can be withdrawn. We currently have a limited number of sites in high water stress areas, but we expect that to increase to over 20 operational sites by 2050. AbbVie plans to repeat this type of risk assessment every five years or if a significant change occurs to operations locations.

Additionally, AbbVie updates a water risk assessment using the WRI Aqueduct Water Risk Atlas tool on an annual basis for 100% of our operations and research and development sites. In 2022, besides performing the water risk assessment using the WRI tool that spans our entire operations facilities network, we further review the local water sources to understand the site-specific water risks and the mitigation plans implemented by the local water providers or municipalities. Based on all the different aspects reviewed, we determine that there's no substantive water-related risk with high impact on our business. However, we recognize that water risk could be a growing concern and are focusing our attention to identifying water efficiency and water management programs at those high risk sites.

W4.2b

(W4.2b) Why does your organization not consider itself exposed to water risks in its direct operations with the potential to have a substantive financial or strategic impact?

	Primary reason	Please explain
Row 1	Risks exist, but no substantive impact anticipated	AbbVie updates a water risk assessment using the WRI Aqueduct Water Risk Atlas tool on an annual basis for 100% of our operations and research and development sites. In 2022, besides performing the water risk assessment using the WRI tool that spans our entire operations facilities network. While we have a limited number of sites in high water stress areas, AbbVie has set ambitious water-related targets to reduce water withdrawal from all of our operations facilities. We invest in innovative technologies that allow us to use water more efficiently, and we encourage the development of new processes that increase efficiency of our water usage. Innovative practices that have been implemented include installing water efficient cleaning equipment, treating then recycling wastewater, and even capturing rainwater at our sites in Singapore, South San Francisco and Campoverde, Italy.

W4.2c

(W4.2c) Why does your organization not consider itself exposed to water risks in its value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact?

	Primary reason	Please explain
Row 1	Risks exist, but no substantive impact anticipated	<p>In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. Water stress was included in this assessment and 35 of our most critical supplier locations were evaluated, besides the top 20 locations for our downstream third-party logistic warehouses and all 9 of our global third-party data centers. Water Stress was identified as a growing risk across those sites. Both climate change and population density will have a negative impact on the water supplies in the areas where our suppliers operate causing water supplies to become more scarce and limited. There will be a corresponding increase in the cost of water, as well as potential limitations on the amount of water that can be withdrawn. AbbVie will repeat this type of risk assessment every five years or if a significant change occurs to these locations or to the external suppliers.</p> <p>Water scarcity risk for supply chain vendor could result in loss of products or product inputs that supplier provides to AbbVie. One of our strategies is to increase our suppliers diversification to ensure the continuity of our supply chain. Our procurement organization has also been engaging our suppliers through our annual Supplier Sustainability Survey. Our commitment to sustainability means we require our suppliers to maintain fair labor practices, foster worker safety, protect the environment, and actively assess and manage risk. Although AbbVie makes no guarantees to suppliers for future business, key suppliers are incentivized through their sharing of a common interest to assist AbbVie in its environmental footprint reduction achievements - and the overall qualitative assessment of their reputation as an AbbVie supplier.</p>

W4.3

(W4.3) Have you identified any water-related opportunities with the potential to have a substantive financial or strategic impact on your business?

Yes, we have identified opportunities, and some/all are being realized

(W4.3a) Provide details of opportunities currently being realized that could have a substantive financial or strategic impact on your business.

Type of opportunity

Efficiency

Primary water-related opportunity

Improved water efficiency in operations

Company-specific description & strategy to realize opportunity

Abbott Park - Capital reinvestment in aging water utilities equipment at manufacturing site, upgrading purified water system with more water and energy efficient equipment by replacing an aging water still with new Reverse Osmosis technology.

Estimated timeframe for realization

Current - up to 1 year

Magnitude of potential financial impact

Low

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

<Not Applicable>

Potential financial impact figure – minimum (currency)

<Not Applicable>

Potential financial impact figure – maximum (currency)

<Not Applicable>

Explanation of financial impact

Estimate based on more efficient water purification equipment, including water and energy savings.

Type of opportunity

Efficiency

Primary water-related opportunity

Water recovery from sewage management

Company-specific description & strategy to realize opportunity

Barceloneta, Puerto Rico and Tuas, Singapore - In Puerto Rico the site treats wastewater effluent via Reverse Osmosis. This water is then recycled and used in the cooling tower basins on the site. The opportunity for the site is to optimize the process to maximize the use of the system and expand the use of this water to other applications. In Tuas, Singapore the site purchases grey water from the municipality. This water is used in the cooling tower basins on the site. The opportunity for the site is to maximize the use of this water in other applications such as fire protection water and boiler feed water.

Estimated timeframe for realization

Current - up to 1 year

Magnitude of potential financial impact

Medium

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

<Not Applicable>

Potential financial impact figure – minimum (currency)

<Not Applicable>

Potential financial impact figure – maximum (currency)

<Not Applicable>

Explanation of financial impact

The unit cost of water in Puerto Rico is very low due to the fact that the site sources water from an on-site well. The financial return for this project is low. The cost for grey water in Singapore is about 50% of the cost for the potable municipal water. The quantity of water used is relatively low so the financial return for the project is low also.

Type of opportunity

Efficiency

Primary water-related opportunity

Improved water efficiency in operations

Company-specific description & strategy to realize opportunity

Singapore - A project to expand the existing rainwater harvesting has been initiated.

Estimated timeframe for realization

Current - up to 1 year

Magnitude of potential financial impact

Low

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

<Not Applicable>

Potential financial impact figure – minimum (currency)

<Not Applicable>

Potential financial impact figure – maximum (currency)

<Not Applicable>

Explanation of financial impact

The harvested rainwater is used in place of grey water that is purchased from the municipality. The cost of this water is low, and the amount of water harvested is small resulting in a low financial return.

Type of opportunity

Efficiency

Primary water-related opportunity

Improved water efficiency in operations

Company-specific description & strategy to realize opportunity

South San Francisco - A rainwater harvesting system has been designed into a new facility that AbbVie started occupying in 2021.

Estimated timeframe for realization

1 to 3 years

Magnitude of potential financial impact

Low

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

<Not Applicable>

Potential financial impact figure – minimum (currency)

<Not Applicable>

Potential financial impact figure – maximum (currency)

<Not Applicable>

Explanation of financial impact

The rainwater harvesting system is relatively small and only intended to reduce a small amount of municipal water that is used in restroom facilities in the building. The cost of this water is low, and the amount of water harvested is small resulting in a low financial return.

Type of opportunity

Efficiency

Primary water-related opportunity

Improved water efficiency in operations

Company-specific description & strategy to realize opportunity

A rainwater harvesting system has been designed and implemented in the utilities building at our Barceloneta, Puerto Rico site in 2022.

Estimated timeframe for realization

Current - up to 1 year

Magnitude of potential financial impact

Low

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

<Not Applicable>

Potential financial impact figure – minimum (currency)

<Not Applicable>

Potential financial impact figure – maximum (currency)

<Not Applicable>

Explanation of financial impact

The harvested rainwater is used in place of well water and is intended to be used in the cooling tower make-up and fire water reservoir. The financial return is dependence on the amount of rain in a given year.

W6. Governance

W6.1

(W6.1) Does your organization have a water policy?

Yes, we have a documented water policy that is publicly available

W6.1a

(W6.1a) Select the options that best describe the scope and content of your water policy.

	Scope	Content	Please explain
Row 1	Company-wide	Description of business dependency on water Description of business impact on water Commitment to reduce water withdrawal and/or consumption volumes in direct operations Commitment to water stewardship and/or collective action Commitments beyond regulatory compliance Reference to company water-related targets Acknowledgement of the human right to water and sanitation Other, please specify (Reference to World Health Organization)	AbbVie's Water Policy scope was selected to provide a framework for internal policies & procedures. The Water Policy is the cornerstone of a global water technical standard which requires each site to: account for water intakes and discharges; report to corporate water use and conservation key performance indicators; and prevent potential water contamination through the use of administrative and engineering controls.

W6.2

(W6.2) Is there board level oversight of water-related issues within your organization?

Yes

W6.2a

(W6.2a) Identify the position(s) (do not include any names) of the individual(s) on the board with responsibility for water-related issues.

Position of individual or committee	Responsibilities for water-related issues
Board-level committee	AbbVie's Board of Directors and its Public Policy and Sustainability Committee provide oversight on matters related to water-related risks and strategies. The Board of Directors also oversees the enterprise risk management review. AbbVie includes water related issues within the scope of risk management review.

W6.2b

(W6.2b) Provide further details on the board's oversight of water-related issues.

	Frequency that water-related issues are a scheduled agenda item	Governance mechanisms into which water-related issues are integrated	Please explain
Row 1	Scheduled - some meetings	Reviewing and guiding corporate responsibility strategy Reviewing and guiding risk management policies Reviewing and guiding strategy Setting performance objectives	AbbVie maintains an established governance process for oversight and management of our water and environmental sustainability efforts. AbbVie's Public Policy and Sustainability Committee provide oversight on matters related to water-related risks and strategies, with annual updates from executive management on environmental strategy, action plans, objectives, and progress against established sustainability goals. The Board of Directors also oversees the enterprise risk management review as well as Named Executive Officer (NEO) compensation with regards to ESG goals. AbbVie's Public Policy Committee monitors and oversees progress against goals and targets for addressing water-related issues. This includes our absolute target of a 20% reduction in water withdrawal by 2025, as well as our additional 2025 and 2035 sustainability goals.

W6.2d

(W6.2d) Does your organization have at least one board member with competence on water-related issues?

	Board member(s) have competence on water-related issues	Criteria used to assess competence of board member(s) on water-related issues	Primary reason for no board-level competence on water-related issues	Explain why your organization does not have at least one board member with competence on water-related issues and any plans to address board-level competence in the future
Row 1	Yes	There are currently four board members on the Abbvie Public Policy and Sustainability Committee. Board members are considered based on a range of criteria including broad-based business knowledge and relationships, prominence and excellent reputations in their primary fields of endeavor, as well as a global business perspective and commitment to good corporate citizenship, diversity, and ability to commit sufficient time and attention to the activities of the board. They must have demonstrated experience and ability that is relevant to the board's oversight role with respect to AbbVie's business and affairs. AbbVie's 2023 Proxy Statement lists each member of the board, their business experience, and their key contributions to the board. One member of the Public Policy and Sustainability committee has experience in risk management as well as climate change. The other three members of the Public Policy and Sustainability committee have listed experience in ESG, environmental, and sustainability matters.	<Not Applicable>	<Not Applicable>

W6.3

(W6.3) Provide the highest management-level position(s) or committee(s) with responsibility for water-related issues (do not include the names of individuals).

Name of the position(s) and/or committee(s)

Other C-Suite Officer, please specify (Executive Vice President, Operations)

Water-related responsibilities of this position

- Assessing water-related risks and opportunities
- Managing water-related risks and opportunities
- Setting water-related corporate targets
- Monitoring progress against water-related corporate targets

Frequency of reporting to the board on water-related issues

Annually

Please explain

Abbvie's Executive Vice President (EVP) of Operations has direct responsibility for water-related issues. The EVP of Operations is an AbbVie C-suite corporate officer, who reports directly to the CEO, and is responsible for AbbVie's Operations organization, including the Global Environmental, Health & Safety organization. The Executive Vice President of Operations presents to the Public Policy and Sustainability committee on environmental and water related issues at periodic meetings. The update to the board includes environmental strategy, action plans, objectives, and progress against the established environmental sustainability goals for AbbVie.

W6.4

(W6.4) Do you provide incentives to C-suite employees or board members for the management of water-related issues?

	Provide incentives for management of water-related issues	Comment
Row 1	No, and we do not plan to introduce them in the next two years	

W6.5

(W6.5) Do you engage in activities that could either directly or indirectly influence public policy on water through any of the following?

Yes, other

W6.5a

(W6.5a) What processes do you have in place to ensure that all of your direct and indirect activities seeking to influence policy are consistent with your water policy/water commitments?

Our water strategy is established and communicated as our Corporate Water Policy. Our policy states that we will take steps to reduce water use while developing and delivering our products, as well as engaging where there is the opportunity to influence or impact our use, procurement, or conservation of water. AbbVie does not have a documented public commitment for our engagement activities to ensure that they are in line with our Corporate Water Policy. However, in 2021, we enhanced our ESG oversight and governance with the establishment of an ESG Council. The ESG Council ensures strategic, enterprise-aligned delivery on AbbVie's ESG Framework. Chaired by our Vice Chairman, External Affairs and Chief Legal Officer and composed of senior cross functional leaders, the ESG Council's purpose is to champion business sustainability and mitigate business risks by monitoring, reviewing and recommending actions in support of our ESG framework and strategy. The ESG Council meets at minimum once per quarter and maintains sub-committees aligned to AbbVie's material topics which included Environmental Sustainability. This council would have oversight and decision making ability in a situation where engagement with a trade associate may not align with our Corporate Water Policy commitments.

W6.6

(W6.6) Did your organization include information about its response to water-related risks in its most recent mainstream financial report?

No, and we have no plans to do so
2022 AbbVie TCFD Report.pdf

AbbVie has not included information about its response to water-related risks in its most recent mainstream financial report, however, AbbVie created a standalone TCFD report in early 2022 and published an updated version in early 2023. See attached.

W7. Business strategy

W7.1

(W7.1) Are water-related issues integrated into any aspects of your long-term strategic business plan, and if so how?

	Are water-related issues integrated?	Long-term time horizon (years)	Please explain
Long-term business objectives	Yes, water-related issues are integrated	21-30	Water-related issues are integrated into our long-term business objectives, and access to an adequate supply of clean water is deemed a strategically significant concern. In 2020, AbbVie performed a climate physical risk assessment which included water stress. In 2020 only a limited number of operational sites were deemed to be in high water stress locations. By 2050, over 20 of our operational sites will be in high water stress areas. Addressing this issue will be key to meeting our long-term business objectives. Our company has established water reduction targets for 2025 and 2035.
Strategy for achieving long-term objectives	Yes, water-related issues are integrated	11-15	Water-related issues are integrated into our strategy for achieving our long-term objectives. AbbVie has a robust process for Long Range Planning and water-related issues has been integrated as a component for planning for the future at our existing sites as well as the development for new sites across the Long Range Plan. Our company has established water reduction targets for 2025 and 2035 and we have developed a strategy for achieving those targets.
Financial planning	Yes, water-related issues are integrated	5-10	Water-related issues are integrated into our financial planning process. Every site goes through an annual financial planning process where they establish budgets for Utilities (including water) for the following year. Every site also performs a financial planning exercise to look at the financial Long Range Plan across a 5-10 year period. During both of these processes, increases to CapEx and OpEx are evaluated. AbbVie has established an annual Capital fund for environmental issues which includes all projects for water conservation efforts.

W7.2

(W7.2) What is the trend in your organization’s water-related capital expenditure (CAPEX) and operating expenditure (OPEX) for the reporting year, and the anticipated trend for the next reporting year?

Row 1

Water-related CAPEX (+/- % change)
0

Anticipated forward trend for CAPEX (+/- % change)
5

Water-related OPEX (+/- % change)
0

Anticipated forward trend for OPEX (+/- % change)
5

Please explain

The water-related CAPEX spend for the reporting year was effectively flat from the previous level of spend. We anticipate an approximate 5% increase for the next reporting year. The water-related OPEX spend for the reporting year was effectively flat from the previous level of spend. We anticipate an approximate 5% increase for the next reporting year. Our water-related CAPEX/OPEX spend remained flat as there was no additional water-related project with significant spend this past year. However, CAPEX/OPEX was used for projects such as installing water efficient cleaning equipment or rainwater harvesting projects that were cited in the response to W4.3a.

W7.3

(W7.3) Does your organization use scenario analysis to inform its business strategy?

	Use of scenario analysis	Comment
Row 1	Yes	In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. The analysis looked at on how physical hazards such as water stress might change along three climate change scenarios High Warming Scenario (RCP 8.5), Moderate Warming Scenario (RCP 4.5), and High Climate Mitigation Scenario (RCP 2.6). These scenarios are based on the IPCC’s Representative Concentration Pathways (RCP) and are aligned with the TCFD technical guidelines (FSB, 2017). We assessed the impacts of these physical hazards across time horizons of 2025, 2030 and 2050. This physical risk assessment will be repeated every five years or if a significant change occurs within our operational footprint.

W7.3a

(W7.3a) Provide details of the scenario analysis, what water-related outcomes were identified, and how they have influenced your organization's business strategy.

	Type of scenario analysis used	Parameters, assumptions, analytical choices	Description of possible water-related outcomes	Influence on business strategy
Row 1	Climate-related	High Climate Mitigation Scenario (RCP 2.6)	In 2020, AbbVie performed a climate physical risk assessment which included water stress. In 2020 only a limited number of operational sites were deemed to be in high water stress locations. By 2050, over 20 of our operational sites will be in high water stress areas. This poses a significant medium-term and long-term risk.	AbbVie continues to integrate the results and findings from this climate physical risk assessment into our long term planning strategy. One of the initial conclusions from this assessment is that we need to reconsider our sustainability targets related to water. Currently AbbVie has a global absolute reduction water target. We are currently evaluating changes to that target to make it a context-based water target within the next 2 years so that more emphasis is directed towards reducing our water use at high water stress sites.

W7.4

(W7.4) Does your company use an internal price on water?

Row 1

Does your company use an internal price on water?

No, and we do not anticipate doing so within the next two years

Please explain

No comment.

W7.5

(W7.5) Do you classify any of your current products and/or services as low water impact?

	Products and/or services classified as low water impact	Definition used to classify low water impact	Primary reason for not classifying any of your current products and/or services as low water impact	Please explain
Row 1	No, and we do not plan to address this within the next two years	<Not Applicable>	Other, please specify	AbbVie prioritizes our patients and customers and hold ourselves to the highest standards of quality and safety. Our products are designed to meet the efficacy and safety standards. AbbVie has not made any public claims classifying one of our products as low water impact, but we are committed to reducing our environmental impact at every stage of the drug development and delivery process.

W8. Targets

W8.1

(W8.1) Do you have any water-related targets?

Yes

W8.1a

(W8.1a) Indicate whether you have targets relating to water pollution, water withdrawals, WASH, or other water-related categories.

	Target set in this category	Please explain
Water pollution	No, and we do not plan to within the next two years	AbbVie recognizes the importance of access to clean, safe water and sanitation, and understands the potential impacts our operations can have on this vital resource. Our patients, customers and employees depend on this increasingly scarce resource and we are committed to managing and reducing the water we use. We acknowledge our business dependency and potential impact on water and our responsibility beyond regulatory compliance to fulfill obligations for responsible water use, stakeholder awareness and education.
Water withdrawals	Yes	<Not Applicable>
Water, Sanitation, and Hygiene (WASH) services	No, and we do not plan to within the next two years	AbbVie recognizes the importance of access to clean, safe water and sanitation, and understands the potential impacts our operations can have on this vital resource. Our patients, customers and employees depend on this increasingly scarce resource and we are committed to managing and reducing the water we use. We collect and analyze the quantity and quality of our water intake, discharge and consumption at our global manufacturing and research facilities in accordance with the local water permit requirements.
Other	No, and we do not plan to within the next two years	Not applicable

W8.1b

(W8.1b) Provide details of your water-related targets and the progress made.

Target reference number

Target 1

Category of target

Water withdrawals

Target coverage

Company-wide (direct operations only)

Quantitative metric

Reduction in total water withdrawals

Year target was set

2016

Base year

2015

Base year figure

34661.22

Target year

2025

Target year figure

27728.98

Reporting year figure

28942

% of target achieved relative to base year

82.5017598929062

Target status in reporting year

Underway

Please explain

In 2022, AbbVie discontinued the manufacture of a legacy product at our North Chicago manufacturing site, which had required our most energy and water intensive manufacturing process. Following the discontinuation of the product, we experienced a 27% reduction in our global water withdrawal compared to 2021 withdrawal levels.

From a business standpoint, water is an essential raw material for a wide range of our products (both for direct manufacturing and indirect cleaning activities). Every day, our operations rely on water for manufacturing medicines that patients need. As global concern about water scarcity continues to rise, it has become increasingly important for AbbVie to safeguard this vital resource and participate in the protection of our environment. This is a company-wide goal because water is used and must be responsibly managed at all manufacturing and R&D sites globally.

Target reference number

Target 2

Category of target

Water withdrawals

Target coverage

Company-wide (direct operations only)

Quantitative metric

Reduction in total water withdrawals

Year target was set

2016

Base year

2015

Base year figure

34661.22

Target year

2035

Target year figure

17330.61

Reporting year figure

28942

% of target achieved relative to base year

33.000684915303

Target status in reporting year

Underway

Please explain

In 2022, AbbVie discontinued the manufacture of a legacy product at our North Chicago manufacturing site, which had required our most energy and water intensive manufacturing process. Following the discontinuation of the product, we experienced a 27% reduction in our global water withdrawal compared to 2021 withdrawal levels. AbbVie has developed a plan and roadmap to achieve the 50% reduction by 2035.

From a business standpoint, water is an essential raw material for a wide range of our products (both for direct manufacturing and indirect cleaning activities). Every day, our operations rely on water for manufacturing medicines that patients need. As global concern about water scarcity continues to rise, it has become increasingly important

for AbbVie to safeguard this vital resource and participate in protection of our environment. This is a company-wide goal because water is used and must be responsibly managed at all manufacturing and R&D sites globally.

W9. Verification

W9.1

(W9.1) Do you verify any other water information reported in your CDP disclosure (not already covered by W5.1a)?

No, we do not currently verify any other water information reported in our CDP disclosure

W10. Plastics

W10.1

(W10.1) Have you mapped where in your value chain plastics are used and/or produced?

	Plastics mapping	Value chain stage	Please explain
Row 1	Yes	Direct operations Supply chain	Plastic materials used in our direct operations are primarily related to packaging, such as pill bottles, blisters package, pre-fill syringes, etc. Cold chain shippers used to transport our drug products or packaging for bulk tablets may also contain plastic materials. AbbVie's Global Packaging Group identifies and understands where and how plastics are used and tracks the sources of materials that we use.

W10.2

(W10.2) Across your value chain, have you assessed the potential environmental and human health impacts of your use and/or production of plastics?

	Impact assessment	Value chain stage	Please explain
Row 1	Yes	Direct operations Supply chain Product use phase	AbbVie's Global Packaging Group has completed Life Cycle Assessment (LCA) using software tools for 15-25% of the package formats used for our products. The assessments help us determine the environmental impact of our packaging materials and inform where opportunities exist to reduce the environmental impact without compromising the quality of our drug products.

W10.3

(W10.3) Across your value chain, are you exposed to plastics-related risks with the potential to have a substantive financial or strategic impact on your business? If so, provide details.

	Risk exposure	Value chain stage	Type of risk	Please explain
Row 1	Yes	Direct operations Supply chain Product use phase	Regulatory Technology	With the restrictions that might be imposed on per- and polyfluoroalkyl substances (PFAS) in the EU and US in the near future, there is a risk of not being able to find a comparable substitution for plastics packaging. If PFAS are banned now, there is no readily available alternative.

W10.4

(W10.4) Do you have plastics-related targets, and if so what type?

	Targets in place	Target type	Target metric	Please explain
Row 1	Yes	Plastic packaging Plastic goods	Eliminate problematic and unnecessary plastics within our goods Increase the proportion of post-consumer recycled content in plastic goods Increase the proportion of our goods that are recyclable in practice and at scale	AbbVie is aligning our internal packaging targets to the EU Directive on Packaging and Packaging Waste. These targets will be applicable to all packages placed on the market globally. By 2035, all packaging materials shall be widely recyclable (recoverable) and shall include at least 30% post-consumer recycled (PCR) content, with exemptions for sensitive products. Additionally, the empty space of primary and sales packaging shall be minimized, and the space of transport (tertiary) packaging shall not exceed 40% of total interior volume.

W10.5

(W10.5) Indicate whether your organization engages in the following activities.

	Activity applies	Comment
Production of plastic polymers	No	Not applicable
Production of durable plastic components	No	Not applicable
Production / commercialization of durable plastic goods (including mixed materials)	No	Not applicable
Production / commercialization of plastic packaging	Yes	AbbVie operates several plastic injection molding equipment for eyecare products and plastic extruders for injectable drug products.
Production of goods packaged in plastics	Yes	Plastics packaging materials are used to preserve the safety and efficacy of drug products and to ensure that the products can be delivered to the end users in a safe manner.
Provision / commercialization of services or goods that use plastic packaging (e.g., retail and food services)	No	Not applicable

W10.8

(W10.8) Provide the total weight of plastic packaging sold and/or used, and indicate the raw material content.

	Total weight of plastic packaging sold / used during the reporting year (Metric tonnes)	Raw material content percentages available to report	% virgin fossil-based content	% virgin renewable content	% post-industrial recycled content	% post-consumer recycled content	Please explain
Plastic packaging sold		Please select	<Not Applicable>	<Not Applicable>	<Not Applicable>	<Not Applicable>	The total weight of plastic packaging sold/used globally is not readily available.
Plastic packaging used		Please select	<Not Applicable>	<Not Applicable>	<Not Applicable>	<Not Applicable>	The total weight of plastic packaging sold/used globally is not readily available.

W10.8a

(W10.8a) Indicate the circularity potential of the plastic packaging you sold and/or used.

	Percentages available to report for circularity potential	% of plastic packaging that is reusable	% of plastic packaging that is technically recyclable	% of plastic packaging that is recyclable in practice at scale	Please explain
Plastic packaging sold	Please select	<Not Applicable>	<Not Applicable>	<Not Applicable>	The total weight of plastic packaging sold/used globally is not readily available. As such, the percentages for circularity potential information is also not readily available.
Plastic packaging used	Please select	<Not Applicable>	<Not Applicable>	<Not Applicable>	The total weight of plastic packaging sold/used globally is not readily available. As such, the percentages for circularity potential information is also not readily available.

W11. Sign off

W-FI

(W-FI) Use this field to provide any additional information or context that you feel is relevant to your organization's response. Please note that this field is optional and is not scored.

Please note attached files for support and reference including:

1. AbbVie Environmental Stewardship Position (Water)
 2. 2022 Data Assurance Environment and Safety Performance Report (Pg 7-8)
 3. 2023 AbbVie Water Risk Dashboard
 4. AbbVie EHS Technical Standard (T12 Water Management)
 5. 2022 AbbVie ESG Action Report (Pg 14-23)
- AbbVie EHS Technical Standard_T12 Water Management (version 4.0).pdf
2022 AbbVie ESG Action Report.pdf
2022 Data Assurance_Environment and Safety Performance Report.pdf
2023 AbbVie Water Risk Dashboard.pdf
AbbVie Environmental Stewardship Position.pdf

W11.1

(W11.1) Provide details for the person that has signed off (approved) your CDP water response.

	Job title	Corresponding job category
Row 1	Head of Global EHS	Other, please specify (Global Environment, Health, and Safety Vice President)

SW. Supply chain module

SW0.1

(SW0.1) What is your organization's annual revenue for the reporting period?

	Annual revenue
Row 1	58054000000

SW1.1

(SW1.1) Could any of your facilities reported in W5.1 have an impact on a requesting CDP supply chain member?

No facilities were reported in W5.1

SW1.2

(SW1.2) Are you able to provide geolocation data for your facilities?

	Are you able to provide geolocation data for your facilities?	Comment
Row 1	Yes, for all facilities	We are providing the geolocation data for all of our facilities, although some facilities are no longer in operation in 2023.

SW1.2a

(SW1.2a) Please provide all available geolocation data for your facilities.

Identifier	Latitude	Longitude	Comment
Abbott Park, USA	42.302	-87.892	
Barceloneta, Puerto Rico (ABL)	18.428	-66.575	
Barceloneta, Puerto Rico (AbbVie Ltd, APL)	18.435	-66.565	
Campoverde, Italy	41.551	12.704	
Cork, Ireland	51.894	-8.485	
Ludwigshafen, Germany	49.475	8.435	
North Chicago, USA	42.332	-87.835	
Sligo, Ireland	54.285	-8.453	
Sligo Ballytivnan, Ireland	54.286	-8.464	
Worcester, USA	42.275	-71.77	
Wyandotte, USA	42.218	-83.15	
Tuas, Singapore	1.302	103.633	
South San Francisco, USA	37.661	-122.395	
Cambridge, MA	42.374	-71.109	
Branchburg, USA	40.564	-74.71	
Campbell, USA	37.265	-121.957	
Cincinnati, USA	39.153	-84.407	
Clonshaugh, Ireland	53.403	-6.222	
Dublin, USA	37.705	-121.914	
Guarulhos, Brazil	-23.495	-46.549	
Heredia, Costa Rica	9.991	-84.158	
Houston, USA	29.824	-95.461	
Irvine, CA	33.672	-117.854	
Liege, Belgium	50.657	5.499	
Pleasanton, USA	37.699	-121.883	
Pringy, France	45.951	6.113	
Santa Cruz, USA	36.955	-122.054	
Waco, USA	31.487	-97.2	
Westport, Ireland	53.803	-9.512	
Redwood City, USA	37.514	-122.199	AbbVie consolidated three sites in the San Francisco area (Redwood City, South San Francisco, Sunnyvale) into a single site in 2021 located in the South San Francisco area. This site is no longer operating in 2023.
South San Francisco (Pharmacyclics), USA	37.382	-122.004	AbbVie consolidated three sites in the San Francisco area (Redwood City, South San Francisco, Sunnyvale) into a single site in 2021 located in the South San Francisco area. This site is no longer operating in 2023.
South San Francisco (Stemcentryx), USA	37.648	-122.386	AbbVie consolidated three sites in the San Francisco area (Redwood City, South San Francisco, Sunnyvale) into a single site in 2021 located in the South San Francisco area. This site is no longer operating in 2023.
Galway, Ireland	35.276	-9.094	This site is no longer operating in 2023.
Livermore, USA	37.707	-121.706	
Madison, USA	40.763	-74.436	
North Brunswick, USA	40.469	-74.444	This site is no longer operating in 2023.
Bridgewater, USA	40.588	-74.626	This site is no longer operating in 2023.
Liverpool, England	53.345	-2.871	This site is no longer operating in 2023.
Sunrise, USA	26.123	-80.336	This site is no longer operating in 2023.

SW2.1

(SW2.1) Please propose any mutually beneficial water-related projects you could collaborate on with specific CDP supply chain members.

SW2.2

(SW2.2) Have any water projects been implemented due to CDP supply chain member engagement?

No

SW3.1

(SW3.1) Provide any available water intensity values for your organization's products or services.

Product name

Allergan OTC Eye Care Products

Water intensity value

0.0004

Numerator: Water aspect

Water withdrawn

Denominator

US Dollars

Comment

Our water intensity value is water withdrawal in cubic meter per the total sales of OTC Eye Care Products in US Dollars

Submit your response

In which language are you submitting your response?

English

Please confirm how your response should be handled by CDP

	I understand that my response will be shared with all requesting stakeholders	Response permission
Please select your submission options	Yes	Public

Please indicate your consent for CDP to share contact details with the Pacific Institute to support content for its Water Action Hub website.

Yes, CDP may share our Main User contact details with the Pacific Institute

Please confirm below

I have read and accept the applicable Terms